Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Chinook Therapeutics, Inc. KDNY
$22.89
+$0.05 (0.22%)
На 18:03, 12 мая 2023
+31.06%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1419973303.00000000
-
week52high
27.44
-
week52low
12.49
-
Revenue
6128000
-
P/E TTM
-8
-
Beta
0.37651500
-
EPS
-2.89000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Stifel | Buy | 19 авг 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| Stifel | Buy | 28 июн 2022 г. | |
| SVB Leerink | Outperform | Outperform | 23 мая 2022 г. |
| Wedbush | Outperform | 06 янв 2021 г. | |
| Stifel | Buy | Buy | 22 дек 2022 г. |
| Wells Fargo | Overweight | 05 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| King Andrew James | A | 26000 | 26000 | 31 янв 2023 г. |
| King Andrew James | A | 104000 | 104000 | 31 янв 2023 г. |
| King Andrew James | A | 16667 | 8333 | 31 янв 2023 г. |
| King Andrew James | D | 15081 | 3244 | 31 янв 2023 г. |
| King Andrew James | A | 18325 | 8333 | 31 янв 2023 г. |
| BJERKHOLT ERIC | A | 21000 | 21000 | 31 янв 2023 г. |
| BJERKHOLT ERIC | A | 84000 | 84000 | 31 янв 2023 г. |
| BJERKHOLT ERIC | A | 14667 | 7333 | 31 янв 2023 г. |
| BJERKHOLT ERIC | D | 37289 | 2891 | 31 янв 2023 г. |
| BJERKHOLT ERIC | A | 40180 | 7333 | 31 янв 2023 г. |
Новостная лента
Chinook Therapeutics: Best Biotech For Kidney Disease Exposure, With Catalysts
Seeking Alpha
06 янв 2023 г. в 12:21
2023 should be a year of progress on kidney disease, with multiple catalysts lined up from multiple companies. Chinook Therapeutics, Inc. has the best risk-reward based on: i) valuation; ii) diversity of pipeline (ERA and anti-APRIL); and iii) clear catalyst in Q3 2023 (phase 3 ALIGN data of Atrasentan).
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
Investors Business Daily
04 янв 2023 г. в 10:05
A kidney disease treatment from Vera lagged rivals from Chinook and Otsuka, analysts said Wednesday as the biotech stock plummeted. The post Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped appeared first on Investor's Business Daily.
Chinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:00
SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023 at 11:15 am EST, and participate in 1x1 meetings.
Chinook Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire
22 ноя 2022 г. в 16:05
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences:
Chinook Therapeutics (KDNY) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 18:48
Chinook (KDNY) delivered earnings and revenue surprises of -33.87% and 614.57%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?